Gastric Cancer Drugs Market Outlook Highlights The Next Major Growth Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Gastric Cancer Drugs Market Growth From $5.38 Billion In 2026 To $8.14 Billion By 2030 At A CAGR Of 10.9%
The market for gastric cancer therapeutics has recorded significant expansion over recent years, with its valuation increasing from $4.9 billion in 2025 to an anticipated $5.39 billion in 2026, reflecting a compound annual growth rate of 9.9%. A number of factors drove this growth during the historical period, including the rising incidence of gastric cancer, insufficient public knowledge about early detection methods, a continued dependence on traditional chemotherapy approaches, a growing preference for treatment within hospital settings, and the considerable expense associated with branded pharmaceutical products.
The market for gastric cancer drugs is anticipated to experience rapid expansion in the coming years, reaching a projected value of $8.14 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.9%. This forecast period’s growth is fueled by improvements in targeted therapies, a rising uptake of immunotherapies, broader application of precision medicine, the creation of both oral and injectable drug forms, and increased financial support from governments and private entities for cancer research. Key developments shaping this period include the emergence of customized treatments for gastric cancer, the innovation of targeted drug delivery mechanisms, a greater emphasis on combining multiple treatment approaches, the growth of chemotherapy services offered outside hospital settings, and an enhanced focus on supportive care and managing patient symptoms.
Download A Free Sample Report For Comprehensive Market Insights:
Gastric Cancer Drugs Market Development Factors: Which Trends Are Supporting Demand?
The anticipated expansion of the gastric cancer drug market is expected to be driven forward by the rising number of older individuals worldwide. An aging population describes a demographic scenario where a substantial portion of a country or region’s inhabitants are elderly, generally those aged 65 and above. This trend is brought about by a consistent extension of life expectancy alongside a decline in birth rates, leading to a larger share of seniors relative to the overall populace. Elderly patients often have a reduced ability to endure certain cancer therapies, like surgical procedures or chemotherapy. Consequently, there arises a demand for more customized treatment options, including pharmaceutical agents, that cater to the distinct requirements and tolerance levels of older patients. As an illustration, in July 2024, data from the UK Parliament’s House of Commons Library, a governmental body in the United Kingdom, showed that in 2022, 12.7 million people in the UK were aged 65 or over, which made up 19% of the total population. That figure is forecasted to increase to 22.1 million by 2072, representing 27% of the population. As a result, the gastric cancer drug market is predicted to undergo growth in the coming period, fueled by the expanding elderly population.
Gastric Cancer Drugs Market Segments: Where Are The Largest Growth Opportunities?
The gastric cancer drugs market covered in this report is segmented –
1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Subsegments:
1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies
2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab
3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications
Gastric Cancer Drugs Market Transformation Trends: Which Innovations Are Driving Change?
Many pharmaceutical firms in the gastric cancer drugs sector are concentrating on creating advanced products, such as therapies aimed at CLDN18.2, to boost treatment effectiveness and deliver more customized patient options. CLDN18.2-focused therapy involves treatments that zero in on claudin 18.2 (CLDN18.2), a protein predominantly found on certain epithelial tissues like the gastric lining. As an example, in October 2024, Astellas Pharma Inc., headquartered in Japan, secured approval from the US Food and Drug Administration (FDA)—an agency devoted to safeguarding public health—for VYLOY (zolbetuximab). This drug, VYLOY (zolbetuximab), stands as the first CLDN18.2-directed treatment specifically designed for advanced gastric and gastroesophageal junction cancer cases where the tumors are CLDN18.2 positive. It is given alongside chemotherapy regimens built on fluoropyrimidine and platinum. The indication covers adults diagnosed with locally advanced, non-surgical, negative gastric or gastroesophageal junction adenocarcinoma.
Gastric Cancer Drugs Market Major Participants And Competitive Dynamics
Major companies operating in the gastric cancer drugs market are F. Hoffmann-La Roche, Eli Lilly and Company, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Novartis Oncology, Arlak Biotech (India), CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene (China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc. (Japan), Daiichi Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Merck & Co. Inc., Pfizer Inc., Sandoz AG (Novartis), Eurofarma Laboratórios S.A., TUTEUR Argentina / Pierre Fabre Group, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan Laboratories, Gilead Sciences, BMS
Access The Complete Gastric Cancer Drugs Market Report:
Gastric Cancer Drugs Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
